Our Experts

Catherine Humphries

Senior Consultant, Advisory Services

Expertise: Oncology and Rare Disease, Biosimilars, Product Launch, Commercial Strategy

Catherine Humphries is a senior consultant for MMIT’s Advisory Services who helps pharmaceutical and biotech companies solve payer access and managed care challenges. For more than a decade, Cathy has focused on providing recommendations to oncology manufacturers. Her expertise spans many therapeutic areas, including auto-immune diseases, transplantation, cardiology, and vaccines. She holds a Bachelor of Science degree from the University of North Texas.

⟨ Back to Our Experts

Insights by Catherine Humphries

Article | September 5, 2024

Key Benefits of Early Market Access Planning

According to our 2024 State of Patient Access survey, 81% of pharma companies are launching their market access planning much earlier than they did five years ago. By Phase I, one-third of pharma companies are already engaged in market access research, with most pharma companies (54%) engaged by Phase II – III.

On-Demand Webinar | July 25, 2024

Strategies for Early Market Access Planning

This webinar details how and why manufacturers benefit from early market research, using client use cases to show how planning for potential access scenarios leads to greater utilization at launch.

Article | July 25, 2024

Connecting the Dots: Part D Design, the IRA, and Biosimilar Uptake

Although the biosimilar market is expected to continue growing over the next few years, adoption thus far has been somewhat slow and uneven. Recent research published in Health Affairs takes a look at how upcoming provisions of the Inflation Reduction Act (IRA) are likely to impact biosimilar coverage, concluding that both Medicare beneficiaries and the government could realize substantial savings if Part D formularies resembled those of employer-sponsored plans.

Article | November 30, 2023

Humira Biosimilars: Pricing, Contracting and Interchangeability

This has been a significant year for the Humira (adalimumab) biosimilar market. AbbVie’s blockbuster drug Humira, an injectable used to treat a range of inflammatory conditions, saw the end of its 20-year, $200 billion monopoly in January.

Article | November 10, 2022

Will Interchangeability Status Truly Move the Needle With Biosimilars?

When it comes to biosimilars, there seem to be far more questions than answers, specifically when it comes to interchangeability. Now that the FDA has granted three biosimilar products “interchangeable” status—with more to come, surely—how will this development affect the biosimilars market? What do pharma manufacturers, payers and physicians need to know about this designation? And, crucially, how might interchangeability affect biosimilar uptake in 2023 and beyond?

Real-World Data Solutions

Payer Data Intelligence Solutions

Payer and Provider Insights Solutions

Payer and Specialty Pharmacy Solutions

Promotional Solutions

Market Access

Patient Journey

Brand Performance and Strategy

Contracting and Reimbursement